1. OP0233 EFFICACY, SAFETY, AND PHARMACODYNAMIC EFFECTS OF THE BRUTON'S TYROSINE KINASE INHIBITOR, FENEBRUTINIB (GDC-0853), IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS IN A PHASE 2 CONTROLLED STUDY. (2nd June 2020) Authors: Isenberg, D.; Furie, R.; Jones, N. S.; Guibord, P.; Galanter, J.; Lee, C.; Mcgregor, A.; Toth, B.; Rae, J.; Hwang, O.; Lokku, A.; Miranda, P.; De Souza, V.; Jaller-Raad, J.; Maura Fernandes, A.; Garcia Salinas, R.; Chinn, L.; Townsend, M. J.; Morimoto, A.; Tuckwell, K. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PB2196: EQUATOR: A PIVOTAL PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ITOLIZUMAB IN COMBINATION WITH CORTICOSTEROIDS FOR THE INITIAL TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE. (23rd June 2022) Authors: Koreth, J.; Kean, L.; Chinn, L.; Acevedo, L. M.; Bandman, O.; Rothman, J.; Connelly, S.; Thomas, D.; Cutler, C. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 2066 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗